Keratan and Heparan Sulfaturia: Glucosamine-6-Sulfate Sulfatase Deficiency REUBEN MATALON, M.D., Ph .D.,* REBECCA WAPPNER, M.D.,T MINERVA DEANCHING, M.S.,* IRA K

Total Page:16

File Type:pdf, Size:1020Kb

Keratan and Heparan Sulfaturia: Glucosamine-6-Sulfate Sulfatase Deficiency REUBEN MATALON, M.D., Ph .D.,* REBECCA WAPPNER, M.D.,T MINERVA DEANCHING, M.S.,* IRA K ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 12, No. 3 Copyright © 1982, Institute for Clinical Science, Inc. Keratan and Heparan Sulfaturia: Glucosamine-6-Sulfate Sulfatase Deficiency REUBEN MATALON, M.D., Ph .D.,* REBECCA WAPPNER, M.D.,t MINERVA DEANCHING, M.S.,* IRA K. BRANDT, M.D.,f and ALLEN HORWITZ, M.D., Ph .D.* * Department of Pediatrics, Hospital Laboratories, Abraham Lincoln School of Medicine, University of Illinois, Chicago, IL 60612 f Indiana University, Bloomington, IN 47402 \University of Chicago, Chicago, IL 60637 ABSTRACT The pattern of excretion of urinary acid mucopolysaccharides (AMPS) has been helpful to establish the diagnosis of mucopolysaccharidoses. The im­ portance of urine analysis for AMPS and the specific enzyme assays is exemplified in a 3V2 year old Caucasian male with severe mental retardation, small stature, thoracolumbar kyphosis, and dysostosis multiplex. Urine anal­ ysis for AMPS revealed excessive quantities of keratan and heparan sulfate. This mucopolysacchariduria was not associated with hepatosplenomegaly or corneal clouding. Enzymic studies on cultured skin fibroblasts indicated deficiency of N-acetylglucosamine-6-sulfate sulfatase. This enzyme defi­ ciency is different from that responsible for Morquio’s syndrome, and early recognition is essential for proper counseling. Introduction zymatic studies in addition to urine AMPS determination. The enzymic and urine Since the discovery that excessive AMPS heterogeneity of some of the muco­ quantities of acid mucopolysaccharides polysaccharidoses are summarized in ta­ (AMPS) are excreted in the urine of pa­ ble I. It is apparent from the diseases de­ tients with Hurler’s syndrome,4 it became scribed in this table that different enzyme clear that different enzyme defects may defects are responsible for excessive ex­ result in the same mucopolysaccharidu­ cretion of the same AMPS. For example, ria. It was apparent that the diagnostic in the Hurler and Hunter syndromes, der- aids for such patients should include en­ matan and heparan sulfate are excreted, 234 0091-7370/82/0500-0234 $00.90 © Institute for Clinical Science, Inc. KERATAN AND HEPARIN SULFATURIA 235 while in the various Sanfilippo syn­ TABLE I dromes, only haparan sulfate is excreted The Mucopolysaccharidoses in the urine.1,5'7,10,11,17 The excretion of keratan and heparan Urinary Muco- Enzyme sulfates in the urine is yet another syn­ Disease polysaccharides Deficiency drome characterized by N-acetylglucosam- Hurler syndrome Dermatan sulfate ct-L-Iduronidase ine-6-sulfate sulfatase deficiency.16 Such Heparan sulfate (D/H)* Scheie syndrome Dermatan. sulfate a-L-Iduronidase an enzyme defect has been suggested in a (D)t Hurler Scheie Dermatan sulfate a-L-Iduronidase patient of DiFerrante et al.2 However, ex­ "compound” (D) t amination of the cultured fibroblasts of Hunter syndrome Dermatan sulfate Iduronosulfate Heparan sulfate sulfatase DiFerrante’s patient revealed sulfamidase Sanfilippo Heparan sulfate Sulfamidase deficiency and normal activity of N- syndrome A Sanfilippo Heparan sulfate a-N-Acetylglucos- acetylglucosamine-6-sulfate sulfatase. Re­ syndrome B aminidase Sanfilippo Heparan sulfate Acetyl CoA: cently, DiFerrante3 has indicated that on syndrome C a-glucosaminide re-evaluation his patient did not, in fact, N-acetyl-trans- ferase have N-acetylglucosamine-6-sulfate sul­ Sanfilippo Heparan sulfate N-Acetylglucos- fatase deficiency. syndrome D amine-6 -sulfate sulfatase (specific for heparan sulfate Case Report only) The patient, B.J.V., a 3’/2 year old Caucasian male, Morquio Keratan sulfate N-Acetylgalac- syndrome A Chondroitin-6 - tosamine-6 -sul- was the product of an uncomplicated pregnancy. De­ sulfate fate sulfatase velopmental milestones seemed appropriate during and galactose- the first year of life. At 18 months of age, deteriora­ 6 -sulfatase tion of motor skills and somatic deformities such as Morquio Keratan sulfate B-Galactosidase syndrome B gibbus, pectus excavatum, prominence of the me- Maroteaux-Lamy Dermatan sulfate N-Acetylgalac- topic suture, and X-ray findings of dysostosis multi­ syndrome tosamine 4-sul­ plex became evident. At the age of three years, petit fate sulfatase mal seizures started; at 3% years, the child became (Aryl sulfatase blind and was virtually unresponsive. This rapid B) B-Glucuronidase Dermatan sulfate S-Glucuronidase mental deterioration was not associated with cor­ deficiency Heparan sulfate neal clouding, hepatosplenomegaly, or coarse facial Keratan and Keratan sulfate N-Acetylglucos- features. heparan Heparan sulfate amine-6 -sulfate sulfaturia sulfatase (specific for Methods keratan sulfate and heparan Urinary AMPS were isolated using gel sulfate) chromatography with Sephadex G-25 fol­ *D/H indicates iduronidase deficiency for iduronide lowed by precipitation with cetylpyridin- linkages in dermatan (D) and heparan (H) sulfates +D indicates iduronidase deficiency for iduronide ium chloride.5 Heparan sulfate and kera­ linkages in dermatan sulfate only tan sulfate were eluted from Dowex 1x2, Cl-, with step wise increase in concentra­ tions of NaCl, 1.25 M eluted heparan sul­ The keratan sulfate fraction eluted with fate, and 4.0 M eluted keratan sulfate.18 4.0 N NaCl was further characterized by The heparan sulfate fraction was charac­ the lack of N-sulfated hexosamine, the re­ terized by the presence of N-sulfated sistance to chondroitinase digestion, the hexosamine, as determined by the nitrous earbazole to hexosamine ratio of 0.26, the acid reaction,12 the resistance to digestion sulfate to hexosamine ratio of 1.04, and with chondroitinases, and the presence of the presence of glucosamine as the major glucosamine as the major amino sugar in amino sugar (93 percent). The enzyme this fraction (>95 percent). Amino acids deficient in Morquio’s syndrome, N-ace- were anlyzed.* tylgalactosamine-6-sulfate sulfatase, was assayed with a trisaccharide prepared from * Beckman M 121 amino acid analyzer was used. chondroitin- 6 - sulfate: N - acetylgalacto- 236 MATALON, WAPPNER, DEANCHING, BRANDT, AND HORWITZ samine-6-sulfate (/3, 1—>4)-glucuronic acid- TABLE II (/3, 1—>3) - {l-3H}-N-galactosaminitol-6 Urinary Acid Mucopolysaccharides -sulfate.6,8 Chondroitin-6-sulfate was di­ gested with testicular hyaluronidase and Chrondroit in Keratan Heparan the tetrasaccharide fraction was isolated Total AMPS Sulfates* Sulfate Sulfatei by gel chromatography on Sephadex G-25. mg/24 h percent percent percent Normal (n-31) 2.5i 0.8 95 < 2 < 3 The tetrasaccharide was further digested Patient B.J.V. 14.0 15 65 20 Morquio type A 25.0± 5.5 57 40 < 3 with /3-glucuronidase, and the resulting (n=12) trisaccharide was isolated and labeled Sanfilippo 40.0+10.5 12 < 3 85 with tritiated borohydride. type A (n=21) *Dermatan sulfate comprised less than two percent of the N-Acetylglucosamine-6-sulfate sulfa­ fraction. tase, the enzyme deficient in our patient, tBased on N-sulfated hexosamine. was measured with a keratan sulfate de­ rived disaccharide: N-acetylglucosamine- 6-sulfate-/3, 1—>4-{l-3H} galactitol. Low Results sulfated keratan sulfate was isolated from human rib cartilage, treated with /3-endo- Acid mucopolysaccharides in the urine galactosidase and monosulfated disaccha­ are shown in table II. The urinary AMPS ride, was isolated and labeled with trit­ of our patient (B.J.V.) with keratan and iated borohydride.9 heparan sulfaturia are compared with nor­ Enzyme extracts were prepared from mal, Morquio, and Sanfilippo patients. cultured skin fibroblasts grown in modi­ Because of the presence of keratan sulfate fied Eagle medium.15 Cells were dis­ in urine, N-acetylgalactosamine-6-sulfate rupted by sonication and centrifuged at sulfatase, the enzyme deficient in Mor­ 10,000 x g for 10 min; the supernatant was quio syndrome, was assayed using cul­ used for enzymic activity following dial­ tured skin fibroblasts. The results of these ysis against 0.05 M sodium acetate, pH studies, indicated in table III, showed no 5.0. Each incubation mixture contained deficiency of that enzyme activity. In ad­ 40 to 50 ¡A of extract, 5.5 /¿moles (100,000 dition, other lysosomal enzyme activites, cpm) of substrate, 20 fig of bovine serum including /3-galactosidase, were normal. albumin, and 9 jamóle of sodium acetate, The specific enzyme deficiency, N-ace- pH 6.0, in a final volume of 100 fi 1. tylglucosamine-6-sulfate sulfatase, which The activity for N-acetylgalactosamine- is unique to patient B.J.V., is indicated in 6-sulfate sulfatase was determined as the table III. Mixing experiments of fibro­ rate of production of nonsulfated trisac­ blasts from patient B.J.V. and normal charide from the disulfated {3H}-labeled fibroblasts showed no endogenous inhibi­ chondroitin-6-sulfate trisaccharide. tor for N-acetylglucosamine-6-sulfate sul- The activity for N-acetylglucosamine-6- sulfate sulfatase was determined as that TAB L E III fraction of radioactivity which did not Activities of N-Acetylglucosamine-6-sulfatase bind to Dowex 1x2, Cl~, following and N-Acetylgalactosamine-6-sulfatase in the incubation of the tritiated galactitol- Fibroblast Extracts N-acetylglucosamine-6-sulfate with the N-Acetylgalactos- amine-6-sulfate N-Acetyl glucosamine proper enzyme extract. Since Dowex 1 x Sulfatase 6-sulfate Sulfatase 2, Cl- binds anionic compounds, the hy­ drolysis of the sulfate groups results in the pmole/itig protein/hr pmole/mg protein/hr Normal 516 83 recovery of the nonsulfated disaccharide Patient B.J.V. 610 Not detectable in the effluent, while the non reacted ma­ Marguio A 26 90 terial binds to the Dowex column. Sanfilippo A 510 86 KERATAN AND HEPARIN SULFATURIA 237 fatase. Fibroblast extracts from the patient a-L-iduronidase. A situation analogous to of DiFerrante had normal activity for both a-L-iduronidase may exist with N-acetyl- hexosamine-6-sulfatases.2 glucosamine-6-sulfate sulfatase. A defici­ ency in the activity of an isoenzyme spe­ cific for the hydrolysis of sulfate from Discussion and Conclusions carbon 6 in the N-acetylglucosamine in The clinical coürse of this patient with heparan sulfate leads to Sanfilippo D and keratan and heparan sulfaturia is rather heparan sulfaturia.
Recommended publications
  • Epidemiology of Mucopolysaccharidoses Update
    diagnostics Review Epidemiology of Mucopolysaccharidoses Update Betul Celik 1,2 , Saori C. Tomatsu 2 , Shunji Tomatsu 1 and Shaukat A. Khan 1,* 1 Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA; [email protected] (B.C.); [email protected] (S.T.) 2 Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA; [email protected] * Correspondence: [email protected]; Tel.: +302-298-7335; Fax: +302-651-6888 Abstract: Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by a lysosomal enzyme deficiency or malfunction, which leads to the accumulation of glycosaminoglycans in tissues and organs. If not treated at an early stage, patients have various health problems, affecting their quality of life and life-span. Two therapeutic options for MPS are widely used in practice: enzyme replacement therapy and hematopoietic stem cell transplantation. However, early diagnosis of MPS is crucial, as treatment may be too late to reverse or ameliorate the disease progress. It has been noted that the prevalence of MPS and each subtype varies based on geographic regions and/or ethnic background. Each type of MPS is caused by a wide range of the mutational spectrum, mainly missense mutations. Some mutations were derived from the common founder effect. In the previous study, Khan et al. 2018 have reported the epidemiology of MPS from 22 countries and 16 regions. In this study, we aimed to update the prevalence of MPS across the world. We have collected and investigated 189 publications related to the prevalence of MPS via PubMed as of December 2020. In total, data from 33 countries and 23 regions were compiled and analyzed.
    [Show full text]
  • Long-Term Outcomes of Systemic Therapies for Hurler Syndrome: an International Multicenter Comparison
    © American College of Medical Genetics and Genomics ORIGINAL RESEARCH ARTICLE Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison Julie B. Eisengart, PhD1, Kyle D. Rudser, PhD2, Yong Xue, MD, PhD3, Paul Orchard, MD4, Weston Miller, MD4, Troy Lund, MD, PhD4, Ans Van der Ploeg, MD, PhD5, Jean Mercer, RGN, RSCN6, Simon Jones, MBChB7, Karl Eugen Mengel, MD8, Seyfullah Gökce, MD8, Nathalie Guffon, MD9, Roberto Giugliani, MD, PhD10, Carolina F.M. de Souza, MD, PhD10, Elsa G. Shapiro, PhD1,11 and Chester B. Whitley, PhD, MD12 Purpose: Early treatment is critical for mucopolysaccharidosis type I Results: Survival was worse when comparing ERT versus HCT, and (MPS I), justifying its incorporation into newborn screening. Enzyme Untreated versus ERT. The cumulative incidences of hydrocephalus replacement therapy (ERT) treats MPS I, yet presumptions that ERT – and cervical spinal cord compression were greater in ERT versus HCT. cannot penetrate the blood brain barrier (BBB) support recommen- Findings persisted in the sensitivity analysis. dations that hematopoietic cell transplantation (HCT) treat the severe, neurodegenerative form (Hurler syndrome). Ethics precludes rando- Conclusion: As newborn screening widens treatment opportunity for mized comparison of ERT with HCT, but insight into this comparison Hurler syndrome, this examination of early treatment quantifies some is presented with an international cohort of patients with Hurler ERT benefit, supports presumptions about BBB impenetrability, and syndrome who received long-term ERT from a young age. aligns with current guidelines to treat with HCT. Methods: Long-term survival and neurologic outcomes were Genet Med compared among three groups of patients with Hurler syndrome: 18 advance online publication 8 March 2018 treated with ERT monotherapy (ERT group), 54 who underwent HCT (HCT group), and 23 who received no therapy (Untreated).
    [Show full text]
  • Pathophysiology of Mucopolysaccharidosis
    Pathophysiology of Mucopolysaccharidosis Dr. Christina Lampe, MD The Center for Rare Diseases, Clinics for Pediatric and Adolescent Medicine Helios Dr. Horst Schmidt Kliniken, Wiesbaden, Germany Inborn Errors of Metabolism today - more than 500 diseases (~10 % of the known genetic diseases) 5000 genetic diseases - all areas of metabolism involved - vast majority are recessive conditions 500 metabolic disorders - individually rare or very rare - overall frequency around 1:800 50 LSD (similar to Down syndrome) LSDs: 1: 5.000 live births MPS: 1: 25.000 live births 7 MPS understanding of pathophysiology and early diagnosis leading to successful therapy for several conditions The Lysosomal Diseases (LSD) TAY SACHS DIS. 4% WOLMAN DIS. ASPARTYLGLUCOSAMINURIA SIALIC ACID DIS. SIALIDOSIS CYSTINOSIS 4% SANDHOFF DIS. 2% FABRY DIS. 7% POMPE 5% NIEMANN PICK C 4% GAUCHER DIS. 14% Mucopolysaccharidosis NIEMANN PICK A-B 3% MULTIPLE SULPH. DEF. Mucolipidosis MUCOLIPIDOSIS I-II 2% Sphingolipidosis MPSVII Oligosaccharidosis GM1 GANGLIOSIDOSIS 2% MPSVI Neuronale Ceroid Lipofuszinois KRABBE DIS. 5% MPSIVA others MPSIII D A-MANNOSIDOSIS MPSIII C MPSIIIB METACHROMATIC LEUKOD. 8% MPS 34% MPSIIIA MPSI MPSII Initial Description of MPS Charles Hunter, 1917: “A Rare Disease in Two Brothers” brothers: 10 and 8 years hearing loss dwarfism macrocephaly cardiomegaly umbilical hernia joint contractures skeletal dysplasia death at the age of 11 and 16 years Description of the MPS Types... M. Hunter - MPS II (1917) M. Hurler - MPS I (1919) M. Morquio - MPS IV (1929) M. Sanfilippo - MPS III (1963) M. Maroteaux-Lamy - MPS IV (1963) M. Sly - MPS VII (1969) M. Scheie - MPS I (MPS V) (1968) M. Natowicz - MPS IX (1996) The Lysosome Lysosomes are..
    [Show full text]
  • Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment
    International Journal of Molecular Sciences Review Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment Francesca D’Avanzo 1,2 , Laura Rigon 2,3 , Alessandra Zanetti 1,2 and Rosella Tomanin 1,2,* 1 Laboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women’s and Children ‘s Health, University of Padova, Via Giustiniani 3, 35128 Padova, Italy; [email protected] (F.D.); [email protected] (A.Z.) 2 Fondazione Istituto di Ricerca Pediatrica “Città della Speranza”, Corso Stati Uniti 4, 35127 Padova, Italy; [email protected] 3 Molecular Developmental Biology, Life & Medical Science Institute (LIMES), University of Bonn, 53115 Bonn, Germany * Correspondence: [email protected] Received: 17 January 2020; Accepted: 11 February 2020; Published: 13 February 2020 Abstract: Mucopolysaccharidosis type II (MPS II, Hunter syndrome) was first described by Dr. Charles Hunter in 1917. Since then, about one hundred years have passed and Hunter syndrome, although at first neglected for a few decades and afterwards mistaken for a long time for the similar disorder Hurler syndrome, has been clearly distinguished as a specific disease since 1978, when the distinct genetic causes of the two disorders were finally identified. MPS II is a rare genetic disorder, recently described as presenting an incidence rate ranging from 0.38 to 1.09 per 100,000 live male births, and it is the only X-linked-inherited mucopolysaccharidosis. The complex disease is due to a deficit of the lysosomal hydrolase iduronate 2-sulphatase, which is a crucial enzyme in the stepwise degradation of heparan and dermatan sulphate.
    [Show full text]
  • Tepzz¥5Z5 8 a T
    (19) TZZ¥Z___T (11) EP 3 505 181 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.07.2019 Bulletin 2019/27 A61K 38/46 (2006.01) C12N 9/16 (2006.01) (21) Application number: 18248241.4 (22) Date of filing: 28.12.2018 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • DICKSON, Patricia GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Torrance, CA California 90502 (US) PL PT RO RS SE SI SK SM TR • CHOU, Tsui-Fen Designated Extension States: Torrance, CA California 90502 (US) BA ME • EKINS, Sean Designated Validation States: Brooklyn, NY New York 11215 (US) KH MA MD TN • KAN, Shih-Hsin Torrance, CA California 90502 (US) (30) Priority: 28.12.2017 US 201762611472 P • LE, Steven 05.04.2018 US 201815946505 Torrance, CA California 90502 (US) • MOEN, Derek R. (71) Applicants: Torrance, CA California 90502 (US) • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (74) Representative: J A Kemp Torrance, CA 90502 (US) 14 South Square • Phoenix Nest Inc. Gray’s Inn Brooklyn NY 11215 (US) London WC1R 5JJ (GB) (54) PREPARATION OF ENZYME REPLACEMENT THERAPY FOR MUCOPOLYSACCHARIDOSIS IIID (57) The present disclosure relates to compositions for use in a method of treating Sanfilippo syndrome (also known as Sanfilippo disease type D, Sanfilippo D, mu- copolysaccharidosis type IIID, MPS IIID). The method can entail injecting to the spinal fluid of a MPS IIID patient an effective amount of a composition comprising a re- combinant human acetylglucosamine-6-sulfatase (GNS) protein comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and having the en- zymatic activity of the human GNS protein.
    [Show full text]
  • MPS Research Highlights at Worldsymposium 2020
    CME/CE MPS Research Highlights at WORLDSymposium 2020 Barbara Burton, MD Ann & Robert H. Lurie Children’s Hospital of Chicago Chicago, IL Mucopolysaccharidoses • A group of lysosomal storage disorders • Genetic disorders in which mutations in different genes leads to abnormal accumulation of complex carbohydrates • Mucopolysaccharies or glycosaminoglycans • Numerous MPSs and each MPS may also have numerous subtypes • Often have striking skeletal features. May or may not have behavioral/cognitive difficulties NIH Rare Disease Database: MPS. 2019. https://rarediseases.info.nih.gov/diseases/7065/mucopolysaccharidosis Mucopolysaccharidoses MPS Type Common Name Gene Mutation Treatment MPS I Hurler syndrome IDUA HSCT, ERT, symptomatic/supportive MPS II Hunter syndrome IDS ERT, symptomatic/supportive MPS III Sanfilippo syndrome GNS, HGSNAT, Symptomatic/supportive NAGLU, SGSH MPS IV Morquio syndrome GALNS, GLB1 ERT, symptomatic/supportive MPS VI Maroteaux-Lamy syndrome ARSB ERT, symptomatic/supportive MPS VII Sly syndrome GUSB ERT, symptomatic/supportive NIH Rare Disease Database: MPS. 2019. https://rarediseases.info.nih.gov/diseases/7065/mucopolysaccharidosis WORLDSymposium • Annual conference focused on lysosomal storage disorders • MPSs, Fabry disease, Gaucher disease, etc • 4 day event every February • Day 1 & 2 – Basic research • Day 2 & 3 – Translational research • Day 3 & 4 – Clinical research • 446 poster presentation • 84 oral presentations MPS and Reproduction • Peter, Cagle; Atlanta, GA • Can women with MPS have normal menstruation and pregnancy? • Case-control study with 33 MPS women [MPS I (10), MPS IV (17), MPS VI (5), and MPS VII (1)] • Menstrual questionnaire • MPS women scored abnormally higher but difference not statistically significant • Pregnancy • 6 women with MPS had successful pregnancy. • Complications included spotting, gestational diabetes, prolonged labor, and excessive blood loss Peter, Cagle.
    [Show full text]
  • Comparative Study of Idursulfase Beta and Idursulfase in Vitro and in Vivo
    Journal of Human Genetics (2017) 62, 167–174 OPEN Official journal of the Japan Society of Human Genetics www.nature.com/jhg ORIGINAL ARTICLE Comparative study of idursulfase beta and idursulfase in vitro and in vivo Chihwa Kim1, Jinwook Seo2, Yokyung Chung2, Hyi-Jeong Ji3, Jaehyeon Lee2, Jongmun Sohn2, Byoungju Lee2 and Eui-cheol Jo1 Hunter syndrome is an X-linked lysosomal storage disease caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), leading to the accumulation of glycosaminoglycans (GAGs). Two recombinant enzymes, idursulfase and idursulfase beta are currently available for enzyme replacement therapy for Hunter syndrome. These two enzymes exhibited some differences in various clinical parameters in a recent clinical trial. Regarding the similarities and differences of these enzymes, previous research has characterized their biochemical and physicochemical properties. We compared the in vitro and in vivo efficacy of the two enzymes on patient fibroblasts and mouse model. Two enzymes were taken up into the cell and degraded GAGs accumulated in fibroblasts. In vivo studies of two enzymes revealed similar organ distribution and decreased urinary GAGs excretion. Especially, idursulfase beta exhibited enhanced in vitro efficacy for the lower concentration of treatment, in vivo efficacy in the degradation of tissue GAGs and improvement of bones, and revealed lower anti-drug antibody formation. A biochemical analysis showed that both enzymes show largely a similar glycosylation pattern, but the several peaks were different and quantity of aggregates of idursulfase beta was lower. Journal of Human Genetics (2017) 62, 167–174; doi:10.1038/jhg.2016.133; published online 10 November 2016 INTRODUCTION secreted protein and contains eight N-linked glycosylation sites at Mucopolysaccharidosis II (MPS II, Hunter syndrome; OMIM 309900) positions 31, 115, 144, 246, 280, 325, 513 and 537.
    [Show full text]
  • MECHANISMS in ENDOCRINOLOGY: Novel Genetic Causes of Short Stature
    J M Wit and others Genetics of short stature 174:4 R145–R173 Review MECHANISMS IN ENDOCRINOLOGY Novel genetic causes of short stature 1 1 2 2 Jan M Wit , Wilma Oostdijk , Monique Losekoot , Hermine A van Duyvenvoorde , Correspondence Claudia A L Ruivenkamp2 and Sarina G Kant2 should be addressed to J M Wit Departments of 1Paediatrics and 2Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Email The Netherlands [email protected] Abstract The fast technological development, particularly single nucleotide polymorphism array, array-comparative genomic hybridization, and whole exome sequencing, has led to the discovery of many novel genetic causes of growth failure. In this review we discuss a selection of these, according to a diagnostic classification centred on the epiphyseal growth plate. We successively discuss disorders in hormone signalling, paracrine factors, matrix molecules, intracellular pathways, and fundamental cellular processes, followed by chromosomal aberrations including copy number variants (CNVs) and imprinting disorders associated with short stature. Many novel causes of GH deficiency (GHD) as part of combined pituitary hormone deficiency have been uncovered. The most frequent genetic causes of isolated GHD are GH1 and GHRHR defects, but several novel causes have recently been found, such as GHSR, RNPC3, and IFT172 mutations. Besides well-defined causes of GH insensitivity (GHR, STAT5B, IGFALS, IGF1 defects), disorders of NFkB signalling, STAT3 and IGF2 have recently been discovered. Heterozygous IGF1R defects are a relatively frequent cause of prenatal and postnatal growth retardation. TRHA mutations cause a syndromic form of short stature with elevated T3/T4 ratio. Disorders of signalling of various paracrine factors (FGFs, BMPs, WNTs, PTHrP/IHH, and CNP/NPR2) or genetic defects affecting cartilage extracellular matrix usually cause disproportionate short stature.
    [Show full text]
  • Sanfilippo Disease Type D: Deficiency of N-Acetylglucosamine-6- Sulfate Sulfatase Required for Heparan Sulfate Degradation
    Proc. Nat!. Acad. Sci. USA Vol. 77, No. 11, pp. 6822-6826, November 1980 Medical Sciences Sanfilippo disease type D: Deficiency of N-acetylglucosamine-6- sulfate sulfatase required for heparan sulfate degradation (mucopolysaccharidosis/keratan sulfate/lysosomes) HANS KRESSE, EDUARD PASCHKE, KURT VON FIGURA, WALTER GILBERG, AND WALBURGA FUCHS Institute of Physiological Chemistry, Waldeyerstrasse 15, D-4400 Mfinster, Federal Republic of Germany Communicated by Elizabeth F. Neufeld, July 10, 1980 ABSTRACT Skin fibroblasts from two patients who had lippo syndromes and excreted excessive amounts of heparan symptoms of the Sanfilippo syndrome (mucopolysaccharidosis sulfate and keratan sulfate in the urine. His fibroblasts were III) accumulated excessive amounts of hean sulfate and were unable to desulfate N-acetylglucosamine-6-sulfate and the unable to release sulfate from N-acety lucosamine)--sulfate linkages in heparan sulfate-derived oligosaccharides. Keratan corresponding sugar alcohol (17, 18). It was therefore suggested sulfate-derived oligosaccharides bearing the same residue at that N-acetylglucosamine-6-sulfate sulfatase is involved in the the nonreducing end and p-nitrophenyl6sulfo-2-acetamido- catabolism of both types of macromolecules. 2-deoxy-D-ucopyranoside were degraded normally. Kinetic In this paper, we describe a new disease, tentatively desig- differences between the sulfatase activities of normal fibro- nated Sanfilippo disease type D, that is characterized by the blasts were found. These observations suggest that N-acetyl- excessive excretion glucosamine4-6sulfate sulfatase activities degrading heparan clinical features of the Sanfilippo syndrome, sulfate and keratan sulfate, respectively, can be distinguished. of heparan sulfate, and the inability to release inorganic sulfate It is the activity directed toward heparan sulfate that is deficient from N-acetylglucosamine-6-sulfate residues of heparan sul- in these patients; we propose that this deficiency causes Sanfi- fate-derived oligosaccharides.
    [Show full text]
  • Letters to Nature
    letters to nature Received 7 July; accepted 21 September 1998. 26. Tronrud, D. E. Conjugate-direction minimization: an improved method for the re®nement of macromolecules. Acta Crystallogr. A 48, 912±916 (1992). 1. Dalbey, R. E., Lively, M. O., Bron, S. & van Dijl, J. M. The chemistry and enzymology of the type 1 27. Wolfe, P. B., Wickner, W. & Goodman, J. M. Sequence of the leader peptidase gene of Escherichia coli signal peptidases. Protein Sci. 6, 1129±1138 (1997). and the orientation of leader peptidase in the bacterial envelope. J. Biol. Chem. 258, 12073±12080 2. Kuo, D. W. et al. Escherichia coli leader peptidase: production of an active form lacking a requirement (1983). for detergent and development of peptide substrates. Arch. Biochem. Biophys. 303, 274±280 (1993). 28. Kraulis, P.G. Molscript: a program to produce both detailed and schematic plots of protein structures. 3. Tschantz, W. R. et al. Characterization of a soluble, catalytically active form of Escherichia coli leader J. Appl. Crystallogr. 24, 946±950 (1991). peptidase: requirement of detergent or phospholipid for optimal activity. Biochemistry 34, 3935±3941 29. Nicholls, A., Sharp, K. A. & Honig, B. Protein folding and association: insights from the interfacial and (1995). the thermodynamic properties of hydrocarbons. Proteins Struct. Funct. Genet. 11, 281±296 (1991). 4. Allsop, A. E. et al.inAnti-Infectives, Recent Advances in Chemistry and Structure-Activity Relationships 30. Meritt, E. A. & Bacon, D. J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277, 505± (eds Bently, P. H. & O'Hanlon, P. J.) 61±72 (R. Soc. Chem., Cambridge, 1997).
    [Show full text]
  • Hurler Syndrome (Mucopolysaccharidosis Type 1) in a Young Female Patient [Version 1; Peer Review: 3 Approved with Reservations]
    F1000Research 2020, 9:367 Last updated: 06 AUG 2021 CASE REPORT Case Report: Hurler syndrome (Mucopolysaccharidosis Type 1) in a young female patient [version 1; peer review: 3 approved with reservations] Sadaf Saleem Sheikh1, Dipak Kumar Yadav 2, Ayesha Saeed3 1Punjab Medical College, Faisalabad, Pakistan 2Nobel Medical College Teaching Hospital, Biratnagar, Nepal 3The Children’s Hospital, Institute of Child Health, Faisalabad, Pakistan v1 First published: 15 May 2020, 9:367 Open Peer Review https://doi.org/10.12688/f1000research.23532.1 Latest published: 15 May 2020, 9:367 https://doi.org/10.12688/f1000research.23532.1 Reviewer Status Invited Reviewers Abstract Hurler syndrome is a rare autosomal recessive disorder of 1 2 3 mucopolysaccharide metabolism. Here, we present the case of a young female patient who presented with features of respiratory version 1 distress. In addition, the patient had gingival hypertrophy, spaced 15 May 2020 report report report dentition, misaligned eruptive permanent dentition, microdontia, coarse facial features, low set ears, depressed nasal bridge, distended 1. Sanghamitra Satpathi , Hi-Tech Medical abdomen, pectus carinatum, umbilical hernia and J-shaped Sella Turcica on an X-ray of the skull. A diagnosis of Hurler syndrome College and Hospital, Rourkela, India (Mucopolysaccharidosis Type I) was made. The patient was kept on ventilator support from the third day; however, she died on the fifth 2. Alla N. Semyachkina , Research and day of admission. Enzyme replacement modality of treatment can Clinical Institute for Pediatrics of the Pirogov increase a patient's survival rate if an early diagnosis can be made. To Russian National Research Medical the best of our knowledge, only a few cases of Hurler syndrome have been reported in Pakistan.
    [Show full text]
  • Illinois Department of Public Health
    NEWBORN SCREENING OFFICE OF HEALTH PROMOTION 535 W. Jefferson St., 2nd Floor Springfield, IL 62761 Phone: 217-785-8101 Fax: 217-557-5396 Mucopolysaccharidosis Type I (MPS I) Disease (Hurler, Hurler-Scheie and Scheie Syndromes) Information for Physicians and Other Health Care Professionals Definition MPS I disease, also frequently referred to as Hurler syndrome, is an inherited, autosomal recessive lysosomal storage disorder caused by deficiency in the activity of the enzyme alpha-L-iduronidase. This enzyme is responsible for the breakdown of certain glycosaminoglycans (GAGs). Lysosomal accumulation of these GAG molecules results in cell, tissue and organ dysfunction. Clinical Symptoms MPS I is a multisystem disorder and presents in three types with a wide range of symptoms. The severe form, MPS I H, also known as Hurler syndrome, has more severe symptoms that usually start within the first year of life. Symptoms of MPS I may include mental retardation and developmental delays, short stature, stiff joints, speech and hearing impairment, heart and lung disease, enlarged liver and spleen, hernia, coarse facial features, hydrocephalus, spinal compression, pain and a shortened life span. The other subtypes of MPS I are MPS I H-S (Hurler-Scheie syndrome) and MPS I S (Scheie syndrome). Children with MPS I H-S and MPS I S may have normal intelligence with milder symptoms starting later in childhood. Newborn Screening and Definitive Diagnosis In Illinois, newborn screening for MPS I disease is performed by measuring alpha-L-iduronidase enzyme activity. If newborn screening results indicate abnormal activity of this enzyme, referral should be made to a metabolic disease specialist.
    [Show full text]